Navigation Links
Astrazeneca's Investigational Cancer Therapies Revealed at ASCO

CHICAGO, AstraZeneca today announced details of two new investigational cancer therapies at the American Society of Clinical Oncology (ASCO) meeting. AZD2281 (KU-0059436) is a small molecule inhibitor of Poly-ADP Ribose Polymerase (PARP).

PARP is an enzyme involved in Base Excision Repair which is a key pathway in the repair of DNA single-stranded breaks. Inhibiting this DNA repair mechanism, in tandem with a defective DNA repair gene like BRCA1 or BRCA2, is thought to lead to double-stranded DNA breaks that tumor cells are unable to repair, resulting in tumor cell death.

AZD2281 has been studied in a range of tumor types in Phase I studies. The study presented today at ASCO showed that treatment with AZD2281 led to inhibition of PARP functional activity in both surrogate and tumor tissue, and reported that strong signals were detected in hereditary ovarian cancer. Between 5% and 10% of all breast and ovarian cancers are believed to be associated with mutations in the BRCA1 or BRCA2 mutations.

Women with BRCA mutations are reported to have up to an 87% risk of developing breast cancer, and up to a 44% risk of developing ovarian cancer by the age of 70.Professor James Carmichael of AstraZeneca said, "We are delighted to be working with The Royal Marsden Hospital and Netherlands Cancer Institute (NKI) on this study, which is at the forefront of research into new targeted treatments for cancer.

The early results we have seen in patients with hereditary ovarian cancer have encouraged us to move rapidly into the next phase of development for this compound."AZD0530, another investigational compound in Phase II clinical development is an inhibitor of Src in tumours. Src was the first cancer-causing gene to be discovered in the 1970s. Src kinases are a family of molecules that play an important role in cancer growth, spread, apoptosis and cell proliferation.

By inhibiting Src it is hoped that cancer prog ression may be delayed.Preclinical studies have identified AZD0530 as a selective inhibitor of Src activity. In the study data presented today, biomarkers confirmed inhibition of Src in human cancers for the first time.Principal Investigator for the study(1) presented today at ASCO, Jose Baselga MD, Chairman and Professor of Medicine, Vall d'Hebron University Hospital, Barcelona, Spain commented, "The AZD0530 clinical trial program was exceptionally well-designed allowing full evaluation of the optimal methodology for measuring Src activation prior measuring its inhibition by AZD0530.

By collecting as much information early on in our clinical trials we give ourselves the best chance of identifying those patients who could benefit most from treatment with AZD0530 in the future."About AstraZenecaAstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services.

It is one of the world's leading pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.In the United States, AstraZeneca is a $12.44 billion healthcare business with more than 12,000 employees.

For nearly three decades, AstraZeneca has offered drug assistance programs side by side with its medicines, and over the past five years, has provided over $3 billion in savings to more than 1 million patients throughout the US and Puerto Rico. AstraZeneca has been named one of the "100 Best Companies for Working Mothers" by Working Mother magazine and is the only large pharmaceutical company named to FORTUNE magazine's 2007 list of "100 Best Companies to Work For." In 2006, for the fifth consecutive year, Science magazine named AstraZeneca a "Top Employer" on its ranking of the world's most respected biopharmaceutical employers.


'"/>




Related medicine news :

1. Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke
2. New Drug Application Submitted for Investigational Antibiotic Doripenem
3. Fibroids unlikely to Turn Cancerous
4. Virus Level could Predict Cervical Cancer Risk
5. Cancer Doctors Okays Controversial Prostate Therapy
6. Potential New Cancer Gene Identified
7. Consensus on "Combination Therapy" for Breast Cancer
8. Cancers of Colon & Rectum linked to Cigarette Smoking
9. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
10. The Cancer Rumour mill working over time
11. Cancer drugs in development nearly doubled since 1995
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... ... April 28, 2016 , ... ... Discount Cards in the mail from USA Medical Prescription Assistance Program. They are ... , Each mailed package will include a ready-to-use, state-themed card and, in ...
(Date:4/28/2016)... Hollywood, CA (PRWEB) , ... April 28, 2016 , ... ... emergency dental care as soon as possible is essential when it comes to dental ... may make the difference between saving and losing a tooth. Toothaches, knocked-out teeth, chipped ...
(Date:4/28/2016)... ... ... many, a diet is only as good as it looks. No matter how healthy the ... an individual cannot deny the importance of maintaining a healthy diet and the team at ... a product range that could entice people to eat clean and enjoy every moment of ...
(Date:4/28/2016)... ... , ... Dr. Farhan Qureshi has recently added yet another high honor to ... Alexandria Dentist from Find Local Doctors . This recognition is based on ... Local Doctors is an online directory that features these patient reviews, helping consumers conveniently ...
(Date:4/28/2016)... ... April 28, 2016 , ... In an effort to support ... Dynamic Fitness has announced that it will donate $5.00 for every membership sold to ... City of Houston Storm Recovery Fund: http://www.houstonemergency.org/go/doc/2263/2523430 , This ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 27, 2016 Shire plc (LSE: SHP, ... , Chief Financial Officer, will present at the Deutsche Bank ... on Wednesday, May 04, 2016, 10:00 am EDT ... available on the Presentations and Webcasts section of Shire,s Investor ... webcast will be available on this same website for approximately ...
(Date:4/27/2016)... FRANCISCO , April 27, 2016 ... reach over USD 2.14 billion by 2022, according ... Inc.       (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ... technological advancement affecting the efficiency and accuracy delivered ... the persistent demand for novel urinalysis instruments and ...
(Date:4/26/2016)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO) is pleased to ... D., to Vice President of Education and Quality. ... continue to lead and oversee Diplomat University, an innovative ... training to Diplomat employees and external professionals on topics ... houses the quality assurance department, which focuses on programs ...
Breaking Medicine Technology: